{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T20:35:05Z","timestamp":1791578105338,"version":"4.3.4"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000957","name":"Alzheimer's Association","doi-asserted-by":"publisher","award":["23AARF-1026883"],"award-info":[{"award-number":["23AARF-1026883"]}],"id":[{"id":"10.13039\/100000957","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The canonical Alzheimer\u2019s Disease (AD) pathological cascade posits that the accumulation of amyloid beta (A\u03b2) is the initiating event, accelerating the accumulation of tau in the entorhinal cortex (EC), which subsequently spreads into the neocortex. Here in a multi-cohort study (ADNI, A4, HABS-HD) of 1354 participants with multimodal imaging and genetic information we queried how genetic variation affects these stages of the AD cascade. We observed that females and\n                    <jats:italic>APOE<\/jats:italic>\n                    -\u03b54 homozygotes are more susceptible to the effects of A\u03b2 on the primary accumulation of tau, with greater EC tau for a given level of A\u03b2. Furthermore, we observed for individuals who have rare risk variants in\n                    <jats:italic>TREM2<\/jats:italic>\n                    and\/or\n                    <jats:italic>APOE<\/jats:italic>\n                    -\u03b54 homozygotes there was a greater spread of primary tau from the EC into the neocortex. These findings offer insights into the function of sex, APOE and microglia in AD progression and have implications for determining personalised treatment with drugs targeting A\u03b2 and tau.\n                  <\/jats:p>","DOI":"10.1038\/s41467-025-60370-8","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T08:31:07Z","timestamp":1751358667000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Variable and interactive effects of Sex, APOE \u03b54 and TREM2 on the deposition of tau in entorhinal and neocortical regions"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3704-5977","authenticated-orcid":false,"given":"Joseph","family":"Giorgio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Jonson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yilin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7274-2634","authenticated-orcid":false,"given":"Jennifer S.","family":"Yokoyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingshen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4458-113X","authenticated-orcid":false,"given":"William J.","family":"Jagust","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"On behalf of the Alzheimer\u2019s Disease Neuroimaging Initiative","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"key":"60370_CR1","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1126\/science.1072994","volume":"297","author":"J Hardy","year":"2002","unstructured":"Hardy, J. & Selkoe, D. J. The amyloid hypothesis of Alzheimer\u2019s disease: Progress and problems on the road to therapeutics. Science 297, 353\u2013356 (2002).","journal-title":"Science"},{"key":"60370_CR2","doi-asserted-by":"publisher","first-page":"5481","DOI":"10.1038\/s41380-021-01249-0","volume":"26","author":"H Hampel","year":"2021","unstructured":"Hampel, H. et al. The amyloid-\u03b2 pathway in Alzheimer\u2019s disease. Mol. Psychiatry 26, 5481\u20135503 (2021).","journal-title":"Mol. Psychiatry"},{"key":"60370_CR3","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa1202753","volume":"367","author":"RJ Bateman","year":"2012","unstructured":"Bateman, R. J. et al. Clinical and biomarker changes in dominantly inherited Alzheimer\u2019s disease. N. Engl. J. Med. 367, 795\u2013804 (2012).","journal-title":"N. Engl. J. Med."},{"key":"60370_CR4","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41583-021-00533-w","volume":"23","author":"GB Frisoni","year":"2021","unstructured":"Frisoni, G. B. et al. The probabilistic model of Alzheimer disease: the amyloid hypothesis revised. Nat. Rev. Neurosci. 23, 53\u201366 (2021).","journal-title":"Nat. Rev. Neurosci."},{"key":"60370_CR5","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/S1474-4422(23)00128-X","volume":"22","author":"WJ Jagust","year":"2023","unstructured":"Jagust, W. J., Teunissen, C. E. & DeCarli, C. The complex pathway between amyloid \u03b2 and cognition: implications for therapy. Lancet Neurol. 22, 847\u2013857 (2023).","journal-title":"Lancet Neurol."},{"key":"60370_CR6","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1001\/jamaneurol.2023.3599","volume":"80","author":"ME Belloy","year":"2023","unstructured":"Belloy, M. E. et al. APOE Genotype and Alzheimer disease risk across age, sex, and population ancestry. JAMA Neurol. 80, 1284\u20131294 (2023).","journal-title":"JAMA Neurol."},{"key":"60370_CR7","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1038\/s41591-024-02931-w","volume":"30","author":"J Fortea","year":"2024","unstructured":"Fortea, J. et al. APOE4 homozygosity represents a distinct genetic form of Alzheimer\u2019s disease. Nat. Med. 30, 1284\u20131291 (2024).","journal-title":"Nat. Med."},{"key":"60370_CR8","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.3233\/JAD-180507","volume":"65","author":"C Dang","year":"2018","unstructured":"Dang, C. et al. Relationship between amyloid-\u03b2 positivity and progression to mild cognitive impairment or dementia over 8 years in cognitively normal older adults. J. Alzheimers Dis. 65, 1313\u20131325 (2018).","journal-title":"J. Alzheimers Dis."},{"key":"60370_CR9","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41582-019-0228-7","volume":"15","author":"Y Yamazaki","year":"2019","unstructured":"Yamazaki, Y., Zhao, N., Caulfield, T. R., Liu, C. C. & Bu, G. Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies. Nat. Rev. Neurol. 15, 501\u2013518 (2019).","journal-title":"Nat. Rev. Neurol."},{"key":"60370_CR10","doi-asserted-by":"publisher","first-page":"4002","DOI":"10.1172\/JCI36663","volume":"118","author":"R Deane","year":"2008","unstructured":"Deane, R. et al. apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. J. Clin. Invest. 118, 4002\u20134013 (2008).","journal-title":"J. Clin. Invest."},{"key":"60370_CR11","doi-asserted-by":"crossref","unstructured":"Castellano, J. M. et al. Human apoE isoforms differentially regulate brain amyloid-\u03b2 peptide clearance. Sci. Transl. Med. 3 (2011).","DOI":"10.1126\/scitranslmed.3002156"},{"key":"60370_CR12","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41583-023-00776-9","volume":"25","author":"J Blumenfeld","year":"2024","unstructured":"Blumenfeld, J., Yip, O., Kim, M. J. & Huang, Y. Cell type-specific roles of APOE4 in Alzheimer disease. Nat. Rev. Neurosci. 25, 91\u2013110 (2024).","journal-title":"Nat. Rev. Neurosci."},{"key":"60370_CR13","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.neuron.2008.04.010","volume":"58","author":"Q Jiang","year":"2008","unstructured":"Jiang, Q. et al. ApoE promotes the proteolytic degradation of A\u03b2. Neuron 58, 681\u2013693 (2008).","journal-title":"Neuron"},{"key":"60370_CR14","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1523\/JNEUROSCI.4315-03.2004","volume":"24","author":"WJ Brecht","year":"2004","unstructured":"Brecht, W. J. et al. Neuron-specific apolipoprotein e4 proteolysis is associated with increased tau phosphorylation in brains of transgenic mice. J. Neurosci. 24, 2527\u20132534 (2004).","journal-title":"J. Neurosci."},{"key":"60370_CR15","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/nature24016","volume":"549","author":"Y Shi","year":"2017","unstructured":"Shi, Y. et al. ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. Nature 549, 523\u2013527 (2017).","journal-title":"Nature"},{"key":"60370_CR16","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1038\/s41577-023-00837-1","volume":"23","author":"M Colonna","year":"2023","unstructured":"Colonna, M. The biology of TREM receptors. Nat. Rev. Immunol. 23, 580\u2013594 (2023).","journal-title":"Nat. Rev. Immunol."},{"key":"60370_CR17","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.neuron.2017.02.042","volume":"94","author":"JD Ulrich","year":"2017","unstructured":"Ulrich, J. D., Ulland, T. K., Colonna, M. & Holtzman, D. M. Elucidating the role of TREM2 in Alzheimer\u2019s disease. Neuron 94, 237\u2013248 (2017).","journal-title":"Neuron"},{"key":"60370_CR18","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/s41582-018-0072-1","volume":"14","author":"TK Ulland","year":"2018","unstructured":"Ulland, T. K. & Colonna, M. TREM2 - a key player in microglial biology and Alzheimer disease. Nat. Rev. Neurol. 14, 667\u2013675 (2018).","journal-title":"Nat. Rev. Neurol."},{"key":"60370_CR19","doi-asserted-by":"crossref","unstructured":"Hou, J., Chen, Y., Grajales-Reyes, G. & Colonna, M. TREM2 dependent and independent functions of microglia in Alzheimer\u2019s disease. Mol. Neurodegener. 17 (2022).","DOI":"10.1186\/s13024-022-00588-y"},{"key":"60370_CR20","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.3233\/JAD-181038","volume":"68","author":"SL Zhou","year":"2019","unstructured":"Zhou, S. L. et al. TREM2 Variants and neurodegenerative diseases: a systematic review and meta-analysis. J. Alzheimers Dis. 68, 1171\u20131184 (2019).","journal-title":"J. Alzheimers Dis."},{"key":"60370_CR21","doi-asserted-by":"crossref","unstructured":"Zhu, B. et al. Trem2 deletion enhances tau dispersion and pathology through microglia exosomes. Mol. Neurodegener. 17 (2022).","DOI":"10.1186\/s13024-022-00562-8"},{"key":"60370_CR22","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.jalz.2016.07.004","volume":"13","author":"W Song","year":"2017","unstructured":"Song, W. et al. Alzheimer\u2019s disease-associated TREM2 variants exhibit either decreased or increased ligand-dependent activation. Alzheimer\u2019s Dement. 13, 381\u2013387 (2017).","journal-title":"Alzheimer\u2019s Dement."},{"key":"60370_CR23","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s40478-016-0367-7","volume":"4","author":"DW Sirkis","year":"2016","unstructured":"Sirkis, D. W. et al. Rare TREM2 variants associated with Alzheimer\u2019s disease display reduced cell surface expression. Acta Neuropathol. Commun. 4, 98 (2016).","journal-title":"Acta Neuropathol. Commun."},{"key":"60370_CR24","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/S1474-4422(18)30232-1","volume":"17","author":"S Carmona","year":"2018","unstructured":"Carmona, S. et al. The role of TREM2 in Alzheimer\u2019s disease and other neurodegenerative disorders. Lancet Neurol. 17, 721\u2013730 (2018).","journal-title":"Lancet Neurol."},{"key":"60370_CR25","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.3233\/JAD-180141","volume":"64","author":"CR Beam","year":"2018","unstructured":"Beam, C. R. et al. Differences between women and men in incidence rates of dementia and Alzheimer\u2019s disease. J. Alzheimers Dis. 64, 1077 (2018).","journal-title":"J. Alzheimers Dis."},{"key":"60370_CR26","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1093\/jnen\/nlw047","volume":"75","author":"JR Filon","year":"2016","unstructured":"Filon, J. R. et al. Gender differences in Alzheimer disease: brain atrophy, histopathology burden, and cognition. J. Neuropathol. Exp. Neurol. 75, 748 (2016).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"60370_CR27","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1007\/s00401-018-1908-x","volume":"136","author":"AM Liesinger","year":"2018","unstructured":"Liesinger, A. M. et al. Sex and age interact to determine clinicopathologic differences in Alzheimer\u2019s disease. Acta Neuropathol. 136, 873 (2018).","journal-title":"Acta Neuropathol."},{"key":"60370_CR28","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1007\/s00401-018-1920-1","volume":"136","author":"S Oveisgharan","year":"2018","unstructured":"Oveisgharan, S. et al. Sex differences in Alzheimer\u2019s disease and common neuropathologies of aging. Acta Neuropathol. 136, 887 (2018).","journal-title":"Acta Neuropathol."},{"key":"60370_CR29","doi-asserted-by":"publisher","first-page":"3805","DOI":"10.1093\/brain\/awaa327","volume":"143","author":"R Smith","year":"2020","unstructured":"Smith, R. et al. The accumulation rate of tau aggregates is higher in females and younger amyloid-positive subjects. Brain 143, 3805\u20133815 (2020).","journal-title":"Brain"},{"key":"60370_CR30","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1001\/jamaneurol.2018.4693","volume":"76","author":"RF Buckley","year":"2019","unstructured":"Buckley, R. F. et al. Sex differences in the association of global amyloid and regional tau deposition measured by positron emission tomography in clinically normal older adults. JAMA Neurol. 76, 542\u2013551 (2019).","journal-title":"JAMA Neurol."},{"key":"60370_CR31","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1002\/ana.25878","volume":"88","author":"RF Buckley","year":"2020","unstructured":"Buckley, R. F. et al. Sex mediates relationships between regional tau pathology and cognitive decline. Ann. Neurol. 88, 921\u2013932 (2020).","journal-title":"Ann. Neurol."},{"key":"60370_CR32","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.neurobiolaging.2021.04.003","volume":"105","author":"L Edwards","year":"2021","unstructured":"Edwards, L. et al. Multimodal neuroimaging of sex differences in cognitively impaired patients on the Alzheimer\u2019s continuum: greater tau-PET retention in females. Neurobiol. Aging 105, 86\u201398 (2021).","journal-title":"Neurobiol. Aging"},{"key":"60370_CR33","doi-asserted-by":"publisher","first-page":"3536","DOI":"10.1093\/brain\/awac257","volume":"145","author":"KB Casaletto","year":"2022","unstructured":"Casaletto, K. B. et al. Sex-specific effects of microglial activation on Alzheimer\u2019s disease proteinopathy in older adults. Brain 145, 3536 (2022).","journal-title":"Brain"},{"key":"60370_CR34","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH Van Dyck","year":"2023","unstructured":"Van Dyck, C. H. et al. Lecanemab in early Alzheimer\u2019s disease. N. Engl. J. Med. 388, 142\u2013143 (2023).","journal-title":"N. Engl. J. Med."},{"key":"60370_CR35","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims, J. R. et al. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA 330, 512\u2013527 (2023).","journal-title":"JAMA"},{"key":"60370_CR36","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1093\/brain\/awy059","volume":"141","author":"CR Jack","year":"2018","unstructured":"Jack, C. R. et al. Longitudinal tau PET in ageing and Alzheimer\u2019s disease. Brain 141, 1517\u20131528 (2018).","journal-title":"Brain"},{"key":"60370_CR37","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1038\/s41591-018-0004-z","volume":"24","author":"C Wang","year":"2018","unstructured":"Wang, C. et al. Gain of toxic apolipoprotein E4 effects in human iPSC-derived neurons is ameliorated by a small-molecule structure corrector. Nat. Med. 24, 647\u2013657 (2018).","journal-title":"Nat. Med."},{"key":"60370_CR38","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1002\/ana.25455","volume":"85","author":"AR Wadhwani","year":"2019","unstructured":"Wadhwani, A. R., Affaneh, A., Van Gulden, S. & Kessler, J. A. Neuronal apolipoprotein E4 increases cell death and phosphorylated tau release in alzheimer disease. Ann. Neurol. 85, 726\u2013739 (2019).","journal-title":"Ann. Neurol."},{"key":"60370_CR39","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/s43587-023-00368-3","volume":"3","author":"N Koutsodendris","year":"2023","unstructured":"Koutsodendris, N. et al. Neuronal APOE4 removal protects against tau-mediated gliosis, neurodegeneration and myelin deficits. Nat. Aging 3, 275\u2013296 (2023).","journal-title":"Nat. Aging"},{"key":"60370_CR40","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1016\/j.neuron.2021.03.024","volume":"109","author":"C Wang","year":"2021","unstructured":"Wang, C. et al. Selective removal of astrocytic APOE4 strongly protects against tau-mediated neurodegeneration and decreases synaptic phagocytosis by microglia. Neuron 109, 1657\u20131674.e7 (2021).","journal-title":"Neuron"},{"key":"60370_CR41","doi-asserted-by":"publisher","unstructured":"Rao, A. et al. Microglia depletion reduces human neuronal APOE4-driven pathologies in a chimeric Alzheimer\u2019s disease model. bioRxivhttps:\/\/doi.org\/10.1101\/2023.11.10.566510 (2023).","DOI":"10.1101\/2023.11.10.566510"},{"key":"60370_CR42","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/s41586-024-07185-7","volume":"628","author":"MS Haney","year":"2024","unstructured":"Haney, M. S. et al. APOE4\/4 is linked to damaging lipid droplets in Alzheimer\u2019s disease microglia. Nature 628, 154\u2013161 (2024).","journal-title":"Nature"},{"key":"60370_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-017-01444-0","volume":"8","author":"T Nuriel","year":"2017","unstructured":"Nuriel, T. et al. Neuronal hyperactivity due to loss of inhibitory tone in APOE4 mice lacking Alzheimer\u2019s disease-like pathology. Nat. Commun. 8, 1\u201314 (2017).","journal-title":"Nat. Commun."},{"key":"60370_CR44","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.neuron.2023.11.014","volume":"112","author":"J Giorgio","year":"2024","unstructured":"Giorgio, J., Adams, J. N., Maass, A., Jagust, W. J. & Breakspear, M. Amyloid induced hyperexcitability in default mode network drives medial temporal hyperactivity and early tau accumulation. Neuron 112, 676\u2013686.e4 (2024).","journal-title":"Neuron"},{"key":"60370_CR45","doi-asserted-by":"crossref","unstructured":"Ferrari-Souza, J. P. et al. APOE\u03b54 associates with microglial activation independently of A\u03b2 plaques and tau tangles. Sci. Adv. 9 (2023).","DOI":"10.1126\/sciadv.ade1474"},{"key":"60370_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13024-022-00590-4","volume":"18","author":"CB Young","year":"2023","unstructured":"Young, C. B. et al. APOE effects on regional tau in preclinical Alzheimer\u2019s disease. Mol. Neurodegener. 18, 1\u201314 (2023).","journal-title":"Mol. Neurodegener."},{"key":"60370_CR47","doi-asserted-by":"crossref","first-page":"e650","DOI":"10.1212\/WNL.0000000000011270","volume":"96","author":"R La Joie","year":"2021","unstructured":"La Joie, R. et al. Association of APOE4 and clinical variability in Alzheimer disease with the pattern of tau- and amyloid-PET. Neurology 96, e650\u2013e661 (2021).","journal-title":"Neurology"},{"key":"60370_CR48","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1001\/jamaneurol.2019.4421","volume":"77","author":"J Therriault","year":"2020","unstructured":"Therriault, J. et al. Association of apolipoprotein e \u03b54 with medial temporal tau independent of amyloid-\u03b2. JAMA Neurol. 77, 470\u2013479 (2020).","journal-title":"JAMA Neurol."},{"key":"60370_CR49","doi-asserted-by":"publisher","first-page":"5977","DOI":"10.1038\/s41380-020-0688-6","volume":"26","author":"J Therriault","year":"2020","unstructured":"Therriault, J. et al. APOE\u03b54 potentiates the relationship between amyloid-\u03b2 and tau pathologies. Mol. Psychiatry 26, 5977\u20135988 (2020).","journal-title":"Mol. Psychiatry"},{"key":"60370_CR50","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1038\/s43587-023-00490-2","volume":"3","author":"JP Ferrari-Souza","year":"2023","unstructured":"Ferrari-Souza, J. P. et al. APOE\u03b54 potentiates amyloid \u03b2 effects on longitudinal tau pathology. Nat. Aging 3, 1210\u20131218 (2023).","journal-title":"Nat. Aging"},{"key":"60370_CR51","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.neurobiolaging.2020.05.012","volume":"94","author":"BJ Lopresti","year":"2020","unstructured":"Lopresti, B. J. et al. Influence of apolipoprotein-E genotype on brain amyloid load and longitudinal trajectories. Neurobiol. Aging 94, 111\u2013120 (2020).","journal-title":"Neurobiol. Aging"},{"key":"60370_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-91207-1","volume":"11","author":"K Cosker","year":"2021","unstructured":"Cosker, K. et al. Microglial signalling pathway deficits associated with the patient derived R47H TREM2 variants linked to AD indicate inability to activate inflammasome. Sci. Rep. 11, 13316 (2021).","journal-title":"Sci. Rep."},{"key":"60370_CR53","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/j.cell.2015.01.049","volume":"160","author":"Y Wang","year":"2015","unstructured":"Wang, Y. et al. TREM2 lipid sensing sustains the microglial response in an Alzheimer\u2019s disease model. Cell 160, 1061\u20131071 (2015).","journal-title":"Cell"},{"key":"60370_CR54","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s00401-018-01957-y","volume":"137","author":"IC Stancu","year":"2019","unstructured":"Stancu, I. C. et al. Aggregated Tau activates NLRP3\u2013ASC inflammasome exacerbating exogenously seeded and non-exogenously seeded Tau pathology in vivo. Acta Neuropathol. 137, 599\u2013617 (2019).","journal-title":"Acta Neuropathol."},{"key":"60370_CR55","doi-asserted-by":"crossref","unstructured":"Sayed, F. A. et al. AD-linked R47H- TREM2 mutation induces disease-enhancing microglial states via AKT hyperactivation. Sci. Transl. Med. 13 (2021).","DOI":"10.1126\/scitranslmed.abe3947"},{"key":"60370_CR56","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1038\/s41591-021-01456-w","volume":"27","author":"TA Pascoal","year":"2021","unstructured":"Pascoal, T. A. et al. Microglial activation and tau propagate jointly across Braak stages. Nat. Med. 27, 1592\u20131599 (2021).","journal-title":"Nat. Med."},{"key":"60370_CR57","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1038\/s43587-022-00310-z","volume":"2","author":"JB Pereira","year":"2022","unstructured":"Pereira, J. B. et al. Microglial activation protects against accumulation of tau aggregates in nondemented individuals with underlying Alzheimer\u2019s disease pathology. Nat. Aging 2, 1138\u20131144 (2022).","journal-title":"Nat. Aging"},{"key":"60370_CR58","doi-asserted-by":"publisher","first-page":"26043","DOI":"10.1074\/jbc.M115.679043","volume":"290","author":"Y Atagi","year":"2015","unstructured":"Atagi, Y. et al. Apolipoprotein E Is a Ligand for Triggering Receptor Expressed on Myeloid Cells 2 (TREM2). J. Biol. Chem. 290, 26043\u201326050 (2015).","journal-title":"J. Biol. Chem."},{"key":"60370_CR59","doi-asserted-by":"crossref","unstructured":"Kober, D. L. et al. Neurodegenerative disease mutations in TREM2 reveal a functional surface and distinct loss-of-function mechanisms. Elife 5 (2016).","DOI":"10.7554\/eLife.20391"},{"key":"60370_CR60","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.neuron.2016.06.015","volume":"91","author":"FL Yeh","year":"2016","unstructured":"Yeh, F. L., Wang, Y., Tom, I., Gonzalez, L. C. & Sheng, M. TREM2 binds to apolipoproteins, including APOE and CLU\/APOJ, and thereby facilitates uptake of amyloid-beta by microglia. Neuron 91, 328\u2013340 (2016).","journal-title":"Neuron"},{"key":"60370_CR61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-020-19227-5","volume":"11","author":"A McQuade","year":"2020","unstructured":"McQuade, A. et al. Gene expression and functional deficits underlie TREM2-knockout microglia responses in human models of Alzheimer\u2019s disease. Nat. Commun. 11, 1\u201317 (2020).","journal-title":"Nat. Commun."},{"key":"60370_CR62","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/BF00308809","volume":"82","author":"H Braak","year":"1991","unstructured":"Braak, H. & Braak, E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathologica 82, 239\u2013259 (1991).","journal-title":"Acta Neuropathologica"},{"key":"60370_CR63","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/S1474-4422(09)70299-6","volume":"9","author":"CR Jack","year":"2010","unstructured":"Jack, C. R. et al. Hypothetical model of dynamic biomarkers of the Alzheimer\u2019s pathological cascade. Lancet Neurol. 9, 119\u2013128 (2010).","journal-title":"Lancet Neurol."},{"key":"60370_CR64","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1007\/s00401-022-02495-4","volume":"144","author":"B Kim","year":"2022","unstructured":"Kim, B. et al. TREM2 risk variants are associated with atypical Alzheimer\u2019s disease. Acta Neuropathol. 144, 1085\u20131102 (2022).","journal-title":"Acta Neuropathol."},{"key":"60370_CR65","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.ajhg.2014.06.009","volume":"95","author":"S Lee","year":"2014","unstructured":"Lee, S., Abecasis, G. R., Boehnke, M. & Lin, X. Rare-Variant association analysis: study designs and statistical tests. Am. J. Hum. Genet. 95, 5 (2014).","journal-title":"Am. J. Hum. Genet."},{"key":"60370_CR66","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jalz.2014.07.003","volume":"11","author":"WE Klunk","year":"2015","unstructured":"Klunk, W. E. et al. The Centiloid project: standardizing quantitative amyloid plaque estimation by PET. Alzheimer\u2019s Dement. 11, 1\u201315.e4 (2015).","journal-title":"Alzheimer\u2019s Dement."},{"key":"60370_CR67","doi-asserted-by":"crossref","unstructured":"Jin, S. C. et al. TREM2 is associated with increased risk for Alzheimer\u2019s disease in African Americans. Mol. Neurodegener. 10 (2015).","DOI":"10.1186\/s13024-015-0016-9"},{"key":"60370_CR68","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa1211851","volume":"368","author":"R Guerreiro","year":"2013","unstructured":"Guerreiro, R. et al. TREM2 Variants in Alzheimer\u2019s disease. N. Engl. J. Med. 368, 117 (2013).","journal-title":"N. Engl. J. Med."},{"key":"60370_CR69","doi-asserted-by":"publisher","first-page":"5838","DOI":"10.1093\/hmg\/ddu277","volume":"23","author":"SC Jin","year":"2014","unstructured":"Jin, S. C. et al. Coding variants in TREM2 increase risk for Alzheimer\u2019s disease. Hum. Mol. Genet. 23, 5838 (2014).","journal-title":"Hum. Mol. Genet."},{"key":"60370_CR70","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1038\/ng.3916","volume":"49","author":"R Sims","year":"2017","unstructured":"Sims, R. et al. Rare coding variants in PLCG2, ABI3 and TREM2 implicate microglial-mediated innate immunity in Alzheimer\u2019s disease. Nat. Genet. 49, 1373 (2017).","journal-title":"Nat. Genet."},{"key":"60370_CR71","unstructured":"Jonsson, T. et al. Variant of TREM2 associated with the risk of Alzheimer\u2019s disease. N. Engl. J. Med. 368, 107 (2013)."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-60370-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-60370-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-60370-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T09:10:10Z","timestamp":1751361010000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-60370-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":71,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["60370"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-60370-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4804430\/v1","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"assertion":[{"value":"2 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"W.J. serves as a consultant to Biogen, Genentech, CuraSen, Bioclinica, and Novartis. J.S.Y. serves on the scientific advisory board for the Epstein Family Alzheimer\u2019s Research Collaboration. All other authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5812"}}